Late-night inspections were reportedly carried out at the premises of Global Pharma Healthcare Private Limited near Chennai in Tamil Nadu.
The action was taken on 3 February 2023 after US authorities said that eyedrops made by the company could be contaminated with drug-resistant bacteria.
Tamil Nadu Drug Controller and the Central Drug Control Authority carried out the inspection, according to an NDTV report. The team collected samples of raw materials, and eyedrop batches sent to the US.
The US alert came after 55 cases of adverse reactions, including permanent vision loss and one death, allegedly linked to Ezricare Artificial Tears eyedrops.
Also watch: Quixplained: why US red-flagged India-made eyedrops